Skip to main content
. 2018 Apr 12;9:603. doi: 10.3389/fimmu.2018.00603

Table 1.

Custom TaqMan assays used to confirm the upregulation of LTR12 elements by vorinostat treatment.a

LTR12 element Primer and probe set Designation Sequence Length GC% Amplicon size (bp)
rv_007357 Set 1 Forward (sense) GAGCGTATGGCGTTATGTAGTT 22 45.5 114
Probe (sense) TTGAGCCGATGAGATCGCTAAGCC 24 54.0
Reverse (antisense) AGCGGTATGTCCTCCCTTTA 20 50.0

Set 2 Forward (sense) GGAGGAACGAAACACTCATCT 21 47.6 102
Probe (antisense) TGCAACTTTCACAGAGTCGTCTCACC 26 50.0
Reverse (antisense) CGTCTCACCCACTTCAGAAA 20 50.0

rv_007420 Set 1 Forward (sense) GGTAGTGAGAGAGAACGGTATG 22 50.0 124
Probe (sense) TCCTCTGCTCATTCTGGTTGTGCT 24 50.0
Reverse (antisense) CTAAAGAGCTCCCACGGTATAG 22 50.0

rv_010177 Set 1 Forward (sense) ACTCCAGACACACCGTCTTA 20 50.0 96
Probe (sense) ATTGGTAGCTTTCCCGAGTCAGCG 24 54.0
Reverse (antisense) TCATTCCATTCAGGTGGGTTC 21 47.6

aThe “rv” designations from the Human Endogenous Retrovirus Database (HERVd) are listed for each LT12 element. Two primer and probe sets were used for the LTR12 element with designation rv_007357.

GC%, percentage of guanine and cytosine bases in corresponding primer or probe; bp, base pair.